Skip to main content
. 2019 Dec 2;9:18021. doi: 10.1038/s41598-019-54226-7

Figure 3.

Figure 3

SDS-PAGE analysis. Non-reducing and reducing SDS-PAGE analysis of (a,b) ranibizumab D0 (sample 1–6) and D7 (sample 7–12), (c,d) bevacizumab D0 (sample 1–6) and D7 (7–12), and (e,f) ranibizumab D0 (sample 1–6) and D7 (sample 7–12). The images have not been cropped.